• Revenue up 40.6% to $19.86 million
• Net loss increased 49% to $8.06 million
• Advanced Therapies revenue up 361.1% to $6.6 million
• Disbursements revenue up 433.4% to $4.8 million

IDT Australia Limited has reported its financial results for the year ended 30 June 2025, marking the completion of the first stage of its strategic transformation program (Rebuild Strategy) and the transition to the second stage (Sustainability Strategy). The company recorded a second consecutive year of revenue growth, with total FY25 revenue jumping 40.6% year-on-year to $19.86 million. However, net loss increased 49% year-on-year to $8.06 million, which includes the recognition of bad debts of circa $1.2 million relating to two customers defaulting on payments in FY25. The topline growth was underpinned by IDT's Rebuild Strategy, which focused on lifting the utilisation rate and re-establishing IDT as a trusted world-leading contract development and manufacturing organisation (CDMO) for high-value pharmaceutical programs. As a result, plant utilisation increased from around 5% three years ago to around 35% at the end of FY25. The standout performer was the Advanced Therapies vertical, with revenue increasing 361.1% year-on-year to $6.6 million. Disbursements revenue, which covers raw material costs and new equipment charged to customers, also grew strongly, up 433.4% year-on-year to $4.8 million. The API Manufacturing and Specialty Orals verticals saw declines in revenue as the company focused on the higher-value Advanced Therapies business.

IDT Australia is transitioning to the second stage of its transformation program, the Sustainability Strategy, with a focus on delivering best-in-class CDMO solutions that address genuine unmet medical needs and building long-term, profitable contracts that create shared success for both IDT and its partners. The company's vision is to evolve from being the 'go-to' CDMO to becoming the 'best-in-class' CDMO in the Southern Hemisphere, recognized for reliably advancing medicine and solving global health challenges through innovation, quality, and execution.